8 analysts have expressed a variety of opinions on Nurix Therapeutics NRIX over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a ...

Gilead isn’t the first major partner for Nurix either. In 2015 Celgene signed up with the biotech in a deal focused on harnessing the protein degradation system to find drugs that may improve ...

Nurix Therapeutics has a fifty-two week low of $8.11 and a fifty-two week high of $29.56. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -6.53 and a beta of 2.14.

In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price target of $35.00. Jeet Mukherjee has given his Buy ...

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its price objective lifted by analysts at Morgan Stanley from $16.00 to $17.00 in a research report issued to clients and investors on ...

SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

2025 Goals and Catalysts: NX-5948: Initiate pivotal studies for NX-5948: Nurix is evaluating NX-5948 in an ongoing Phase 1b clinical trial in adults with relapsed or refractory B-cell malignancies ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAN FRANCISCO - Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in targeted protein modulation drugs, announced today the appointment of John Northcott as its new ...